Physician profile
Ashley Mann
NPI 1962931410
$6,656.79
in general payments reported to CMS, 2019-2025
53 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $972 · 2023: $1,406 · 2024: $1,907 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,168.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $736.25 | 2021-2025 | |
| Janssen Biotech, INC. | $585.11 | 2021-2025 | Darzalex, Erleada, Talvey |
| Celgene Corporation | $398.66 | 2021-2025 | Reblozyl, Opdualag |
| Regeneron Healthcare Solutions, INC. | $389.53 | 2022-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $357.96 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Merck Sharp & Dohme LLC | $315.65 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Exelixis INC. | $233.23 | 2021-2025 | Cabometyx |
| Daiichi Sankyo INC. | $217.06 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $207.22 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
| Astrazeneca Pharmaceuticals LP | $207.20 | 2021-2025 | Imfinzi, Calquence, Lynparza |
| Eisai INC. | $202.45 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.35 | 2023-2025 | |
| Beigene USA, INC. | $180.02 | 2021-2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $149.58 | 2021-2023 | Imbruvica |
| Abbvie INC. | $142.12 | 2022-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $132.52 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmaessentia USA Corporation | $132.42 | 2023-2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $132.04 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Pfizer INC. | $127.20 | 2023-2024 | |
| Genentech USA, INC. | $114.50 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Glaxosmithkline, LLC. | $114.04 | 2021-2025 | Ojjaara, Blenrep, Zejula |
| Stemline Therapeutics INC. | $106.59 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $98.04 | 2022-2024 | Soliris, Ultomiris |
| Genzyme Corporation | $86.95 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $75.22 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $69.91 | 2022-2024 | Onivyde, Somatuline Depot |
| Aveo Pharmaceuticals, INC. | $68.40 | 2022-2025 | Fotivda |
| Genmab U.S., INC. | $61.86 | 2023-2024 | Epkinly |
| Seagen INC. | $58.62 | 2022-2023 | Padcev, Tukysa |
| Amgen INC. | $55.69 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.50 | 2022-2024 | Opdivo |
| Adc Therapeutics America, INC. | $52.64 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $52.49 | 2024-2025 | Monoferric, Cosela |
| Karyopharm Therapeutics INC. | $49.33 | 2023-2024 | Xpovio |
| Sobi, INC | $49.08 | 2022-2023 | |
| Astellas Pharma US INC | $46.11 | 2024-2025 | Padcev, Xtandi |
| Sun Pharmaceutical Industries INC. | $43.31 | 2024-2025 | |
| Mirati Therapeutics, INC. | $41.76 | 2023 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.62 | 2025 | |
| Agios Pharmaceuticals, INC. | $36.59 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $32.33 | 2025 | Tevimbra |
| Emd Serono, INC. | $29.91 | 2023-2025 | Bavencio |
| Lilly USA, LLC | $25.84 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Tersera Therapeutics LLC | $23.63 | 2025 | Quzyttir |
| G1 Therapeutics, INC. | $18.32 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $17.73 | 2025 | Vivimusta |
| Coherus Oncology, INC. | $16.30 | 2022 | |
| Global Blood Therapeutics, INC. | $15.02 | 2022 | |
| Acrotech Biopharma INC. | $14.06 | 2023 | Beleodaq |
| Apellis Pharmaceuticals, INC. | $13.58 | 2024 | Empaveli |
| Myovant Sciences INC. | $12.82 | 2022 | |
| Kite Pharma, INC. | $12.19 | 2021 | |
| Rigel Pharmaceuticals, INC. | $9.24 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.